![Surviving-an-FDA-GCP-Inspection-500.jpg Surviving an FDA GCP Inspection](https://www.centerwatch.com/ext/resources/products/Surviving-an-FDA-GCP-Inspection-500.jpg?height=200&t=1605810958&width=200)
Home » Drug & Device Pipeline News
Drug & Device Pipeline News
May 2, 2022
Company | Drug/Device | Medical Condition | Status |
---|---|---|---|
Trials Authorized | |||
Gamida Cell | GDA-201 | B-cell lymphomas | IND approved by the FDA |
Moleculin Biotech | WP1066 | Recurrent malignant glioma | IND approved by the FDA |
Quoin Pharmaceuticals | QRX003 | Netherton syndrome | IND approved by the FDA |
Sorrento Therapeutics | STI-9167 (Intravenous COVISHIELD) | COVID-19 | IND approved by the FDA |
Renovion | ARINA-1 | Noncystic fibrosis bronchiectasis | Study may proceed letter issued by the FDA for phase 2 trial |
Direct Biologics | ExoFlo | Acute respiratory distress syndrome due to COVID-19 | Phase 3 trial approved by the FDA |
Alterity Therapeutics | ATH434 | Multiple system atrophy | Phase 2 trial authorized by the UK regulatory authority |
Lemonex | LEM-S401 | Hypertrophic scars | IND approved by South Korea’s regulatory authority |
Trials Initiated | |||
Starton Therapeutics | 24-hour continuous subcutaneous infusion of lenalidomide | Multiple myeloma | Initiation of phase 1 trial in the Netherlands |
Phio Pharmaceuticals | PH-762 | Advanced melanoma | Initiation of phase 1b trial |
Biomind Labs | BMND01 (inhaled formulation of N,N-dimethyltryptamine) | Treatment-resistant depression | Initiation of phase 1/2a trial |
SOTIO Biotech | SOT102 | Gastric and pancreatic cancer | Initiation of phase 1/2 trial |
VITRAC Therapeutics | VIC-1911 | Graft-vs.-host disease prophylaxis | Initiation of phase 1/2 trial |
Arrowhead Pharmaceuticals | ARO-ANG3 | Homozygous familial hypercholesterolemia | Initiation of phase 2 trial |
Fervent Pharmaceuticals | FP-101 | Symptoms of menopause | Initiation of phase 2 trial |
HiberCell | Odetiglucan plus Keytruda (pembrolizumab) | Metastatic, hormone-refractory breast cancer | Initiation of phase 2 trial |
Lyra Therapeutics | LYR-220 | Postsurgical chronic rhinosinusitis | Initiation of phase 2 trial |
Tryp Therapeutics | TRP-8802 in combination with psychotherapy | Binge eating disorder | Initiation of phase 2 trial |
HighTide Therapeutics | HTD1801 | Type 2 diabetes | Initiation of phase 2 trial in China |
Citius Pharmaceuticals | Halo-Lido | Hemorrhoids | Initiation of phase 2b trial |
Harmony Biosciences | Pitolisant | Idiopathic hypersomnia | Initiation of phase 3 trial |
Novavax | NVX-CoV2373, COVID-19 vaccine | COVID-19 | Initiation of phase 3 booster expansion trial in adolescents |
Sedana Medical | Inhaled isoflurane | Sedation of adult mechanically ventilated ICU patients | Initiation of two phase 3 trials |
Approvals | |||
Gilead | Veklury (remdesivir) | COVID-19 in pediatric patients older than 28 days | Approved by the FDA for expanded indication |
Mycovia Pharmaceuticals | Vivjoa (oteseconazole capsules) | Recurrent vulvovaginal candidiasis (chronic yeast infection) | Approved by the FDA |
Biohaven Pharmaceuticals Pfizer |
Vydura (rimegepant) | Acute treatment of migraine and prophylaxis of episodic migraine | Approved by the European Commission |
Vifor Fresenius Medical Care Renal Pharma Cara Therapeutics |
Kapruvia (difelikefalin) | Moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients | Approved by the European Commission |
![To view more CenterWatch Weekly stories, click here.](https://no-cache.hubspot.com/cta/default/4532008/07345fb0-4711-43d9-b045-10bbf88744d8.png)
Upcoming Events
-
21Oct